首页> 外文OA文献 >Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

【2h】

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

机译：Roxadustat（FG-4592）与Epoetin Alfa对比接受维持性血液透析患者的贫血：第2阶段，随机，6到19周，开放标签，活性比较剂，剂量范围，安全性和探索性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Provenzano Robert; Besarab Anatole; Wright Steven; Dua Sohan; Zeig Steven; Nguyen Peter; Poole Lona; Saikali Khalil G.; Saha Gopal; Hemmerich Stefan; Szczech Lynda; Yu K.H. Peony; Neff Thomas B.;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study [J] . Provenzano Robert, Besarab Anatole, Wright Steven, American Journal of Kidney Diseases: The official journal of the National Kidney Foundation . 2016,第6期

机译：Roxadustat（FG-4592）与Epoetin Alfa对比接受维持性血液透析患者的贫血：第2阶段，随机，6到19周，开放标签，活性比较剂，剂量范围，安全性和探索性疗效研究
2. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan [J] . Journal of the American Society of Nephrology: JASN . 2020,第7期

机译：第3阶段，随机，双盲，活性比较器（Darbopoetin Alfa）在日本血液透析性血液透析患者中口服Roxadustat的研究
3. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients [J] . Besarab Anatole, Provenzano Robert, Hertel Joachim, Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association . 2015,第10期

机译：roxadustat（FG-4592）治疗非透析依赖型慢性肾脏病（NDD-CKD）患者的随机安慰剂控制剂量范围和药效学研究
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients [O] . Anatole Besarab, Robert Provenzano, Joachim Hertel, -1

机译：roxadustat（FG-4592）治疗非透析依赖型慢性肾脏病（NDD-CKD）患者的随机安慰剂控制的剂量范围和药效学研究
6. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan [O] . Tadao Akizawa, Manabu Iwasaki, Yusuke Yamaguchi, 2020

机译：第3阶段，随机，双盲，活性比较（Darbopoetin Alfa）在日本血液透析血液透析患者中口腔roxadustat的研究

Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study

著录项

引文网络

相似文献

相关主题

期刊订阅